Menu Search
Equities

WuXi Biologics (Cayman) Inc

2269:HKG

WuXi Biologics (Cayman) Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)16.64
  • Today's Change-0.18 / -1.07%
  • Shares traded84.30m
  • 1 Year change-65.94%
  • Beta1.5732
Data delayed at least 15 minutes, as of Nov 12 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy5
Outperform7
Hold10
Sell0
Strong Sell1

Share price forecast in CNY

The 22 analysts offering 12 month price targets for WuXi Biologics (Cayman) Inc have a median target of 18.16, with a high estimate of 34.82 and a low estimate of 8.46. The median estimate represents a 9.14% increase from the last price of 16.64.
High109.3%34.82
Med9.1%18.16
Low-49.2%8.46

Earnings history & estimates in CNY

WuXi Biologics (Cayman) Inc reported annual 2023 earnings of 1.06 per share on Mar 26, 2024.
Average growth rate+40.68%
More ▼

Revenue history & estimates in CNY

of 10.29bn. This equaled the revenue expectation of the one analyst following the company. The same period last year the company did not report revenues.
WuXi Biologics (Cayman) Inc. had revenues for the full year 2023 of 17.03bn. This was 11.56% above the prior year's results.
Average growth rate+46.04%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.